Drug Profile


Alternative Names: CELENT-07; CELENXT-07; CELEXT-07

Latest Information Update: 16 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator 9305-9954 Quebec
  • Class Antifungals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Onychomycosis

Most Recent Events

  • 01 Aug 2016 Phase-II clinical trials in Onychomycosis in Canada (Topical) (NCT02644551)
  • 29 Dec 2015 9305-9954 Quebec Inc plans a phase II trial for Onychomycosis in Canada (NCT02644551)
  • 01 Dec 2015 Preclinical trials in Onychomycosis in Canada (Topical) before December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top